DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Trandolapril (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Abbott

Official(s) and/or principal investigator(s):
Global Medical Information 1-800-633-9110, Study Director, Affiliation: Abbott

Summary

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Clinical Details

Official title: A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Na´ve and Concurrently Treated Hypertensive Patients (TRAIL)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure

Secondary outcome:

Changes in blood pressure, safety.

BP mmHg incremental and absolute change

Adverse events

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Stage 1 or 2 Hypertension

Exclusion Criteria:

- Uncontrolled diabetes

- Subject has a hypersensitivity to ACE inhibitor

Locations and Contacts

Additional Information

Starting date: March 2004
Last updated: July 18, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017